A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Molecular Changes in Markers of Cell Proliferation and Apoptosis Associated With Treatment
Molecular measures of effect will be measured in tissue obtained at baseline biopsy (paraffin specimen) and on surgical specimen obtained at end of 3 weeks of treatment.
6 months after treatment of last patient enrolled
No
Dennis Holmes
Principal Investigator
USC/Norris Comprehensive Cancer Center
United States: Food and Drug Administration
1B-03-7
NCT00183963
August 2006
June 2008
Name | Location |
---|---|
Norris Comprehensive Cancer Center | Los Angeles, California 90033 |